The report provides an overview of the gene fusion testing market and analyzes market trends. It includes global revenue ($ million) using 2024 as the base year, estimated data for 2025 and projected data for 2026 through 2030.
The market is segmented by technology, indication and end user. By technology, the market is segmented into fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR) and immunohistochemistry (IHC). By indication, it is segmented into hematological cancer and solid tumor. By end user, the market comprises pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, as well as academic and research centers. Geographical regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America.
The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and providing the leading gene fusion testing companies. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments in major companies.
The market is segmented by technology, indication and end user. By technology, the market is segmented into fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR) and immunohistochemistry (IHC). By indication, it is segmented into hematological cancer and solid tumor. By end user, the market comprises pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, as well as academic and research centers. Geographical regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America.
The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and providing the leading gene fusion testing companies. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments in major companies.
The report includes:
- Overview and an analysis of the global market for gene fusion testing technologies
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Understanding of the technology background for fusion genes, their applications in cancer research and long-read transcriptome sequencing data
- Estimates of the current market size and revenue prospects, along with a corresponding market share analysis based on the technology type, disease indication, end user and region
- Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations, prospects and the impact of macroeconomic factors
- Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
- Patent review, featuring key granted and published patents
- Analysis of the industry structure, including companies’ market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Profiles of the leading companies in the market
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Emerging Technologies and Developments
Chapter 5 Market Segmentation Analysis
Chapter 6 Competitive Intelligence
Chapter 7 Appendix
List of Tables
List of Figures
Companies Mentioned
- AmoyDx Diagnostics Co. Ltd.
- Biocare Medical LLC
- Biocartis
- F. Hoffmann-La Roche Ltd.
- Guardant Health Inc.
- Illumina Inc.
- Integrated DNA Technologies Inc.
- Myriad Genetics Inc.
- QIAGEN
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 79 |
| Published | December 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 505 Million |
| Forecasted Market Value ( USD | $ 993.6 Million |
| Compound Annual Growth Rate | 12.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
